CNTB: Rademikibart shows rapid, sustained efficacy and safety in asthma, COPD, and atopic dermatitis
Rademikibart demonstrated strong efficacy and safety in acute asthma, COPD, and atopic dermatitis, with rapid and sustained lung function improvements and a differentiated safety profile versus dupilumab. Market research and clinical data support significant commercial potential, with upcoming mile…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.